Summary We systematically reviewed the literature on the performance of osteoporosis absolute fracture risk assessment instruments. Relatively few studies have evaluated the calibration of instruments in populations separate from their development cohorts, and findings are mixed. Many studies had methodological limitations making susceptibility to bias a concern. Introduction The aim of this study was to systematically review the literature on the performance of osteoporosis clinical fracture risk assessment instruments for predicting absolute fracture risk, or calibration, in populations other than their derivation cohorts. Methods We performed a systematic review, and MEDLINE, Embase, Cochrane Library, and multiple other literature sources were searched. Inclusion and exclusion criteria were applied and data extracted, including information about study participants, study design, potential sources of bias, and predicted and observed fracture probabilities. Results A total of 19,949 unique records were identified for review. Fourteen studies met inclusion criteria. There was substantial heterogeneity among included studies. Six studies assessed the WHO's Fracture Risk Assessment (FRAX) instrument in five separate cohorts, and a variety of risk assessment instruments were evaluated in the remainder of the studies. Approximately half found good instrument calibration, with observed fracture probabilities being close to predicted probabilities for different risk categories. Studies that assessed the calibration of FRAX found mixed performance in different populations. A similar proportion of studies that evaluated simple risk assessment instruments (≤5 variables) found good calibration when compared with studies that assessed complex instruments (>5 variables). Many studies had methodological features making them susceptible to bias. Conclusions Few studies have evaluated the performance or calibration of osteoporosis fracture risk assessment instruments in populations separate from their development cohorts. Findings are mixed, and many studies had methodological limitations making susceptibility to bias a possibility, raising concerns about use of these tools outside of the original derivation cohorts. Further studies are needed to assess the calibration of instruments in different populations prior to widespread use.
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Introduction
Osteoporosis is estimated to affect 200 million people worldwide and the morbidity, mortality, and costs associated with osteoporotic fractures are substantial [1] [2] [3] [4] . Treatment of individuals at increased risk for osteoporotic fracture can reduce fracture risk and improve health outcomes; however, most individuals with osteoporosis are unidentified and untreated [5] [6] [7] . Many national clinical practice guidelines recommend screening for individuals at risk for osteoporotic fracture to identify individuals who may benefit from treatment [8] .
Within the past 20 years, the gold standard test for diagnosing osteoporosis has been dual-energy x-ray absorptiometry (DXA), which measures bone mineral density (BMD). In the past few years, some experts have proposed a shift from use of BMD measures alone to estimation of absolute fracture risk over a period of time by incorporating clinical risk factors to identify individuals at high risk for osteoporotic fracture who may benefit from treatment. This new approach reflects understanding that clinical risk factors, in addition to BMD, have a significant independent impact on fracture risk, and are important to take into account when assessing osteoporotic fracture risk to identify individuals at high risk who may benefit from treatment. The use of clinical fracture risk assessment instruments has been endorsed in several national clinical practice guidelines [8] , and is growing among clinicians.
There are multiple clinical fracture risk assessment instruments currently available, including the frequently used World Health Organization's Fracture Risk Assessment (FRAX) instrument. Many fracture risk assessment instruments have been validated in their development (derivation) populations for prediction of future fracture risk. However, it is important for clinicians, patients, and policymakers to know how well these instruments perform in populations other than their derivation cohort-specifically, how their predicted estimates of absolute fracture risk match observed fracture incidence in different populations in which they may be used-to be confident in their use.
The aim of this study was to systematically review the literature on osteoporosis clinical fracture risk assessment instruments to assess their performance in estimating absolute fracture risk over a given time period; specifically to compare predicted fracture probabilities to observed fracture probabilities (i.e., calibration) at different risk thresholds or categories in populations other than their derivation cohort.
Methods

Data sources and search strategies
We developed literature searches with the assistance of a professional research librarian (AAS) to identify studies that assessed the performance of osteoporosis clinical risk assessment instruments. Our search strategy was designed to identify studies of osteoporosis clinical fracture risk assessment instruments for predicting absolute fracture risk over a period of time, as well as studies of clinical risk assessment instruments for identifying individuals with osteoporosis by DXA criteria. In this study, we report findings for the systematic review of the performance of risk assessment instruments for predicting absolute fracture risk. The search terms used can be found in the complete MEDLINE search strategy which is shown in Supplementary material Table 1 . Search strategies for the other databases are available from the authors upon request.
The following databases were searched: OvidSP MEDLINE (1948- In addition to database searching, the reference lists of relevant original studies and reviews were scanned to identify any additional relevant studies. Furthermore, individual issues of Osteoporosis International, the Journal of Bone and Mineral Research, and Endocrine Reviews , from 1990 to 2011, were handsearched.
Study selection
We developed inclusion and exclusion criteria to select studies for this systematic review of the performance of clinical fracture risk assessment instruments for prediction of absolute fracture risk. We included studies done in adult populations that reported original data; assessed the performance of a clinical fracture risk assessment instrument to predict absolute future fracture risk; and provided predicted and observed fracture probabilities (or sufficient information to determine these probabilities) for different risk thresholds or categories of the instrument evaluated. We included studies of risk assessment instruments that contained a BMD component in addition to clinical risk factors, as long as the instrument had a clinical risk factor component. We included studies published in any language, in any type of adult patient population, in any type of publication (e.g., journal article, abstract, government report, dissertation) with no exclusions for any study participant characteristics.
We excluded studies done in patient populations that were composed of solely individuals with osteoporosis or osteopenia, and studies that did not provide both predicted and observed fracture probabilities (or sufficient data to determine these probabilities) for specific risk instrument thresholds or categories over a period of time. Thus, we excluded studies that only provided "average" predicted and observed probabilities of fracture over time for an entire study population rather than reporting separate performance data for several different risk thresholds or categories, as the "average" performance of an instrument is not sufficiently informative about the risk instrument's performance. For example, a risk assessment instrument could consistently overestimate probability of fracture for individuals of low risk and underestimate probability of fracture for individuals of high risk, and yet have an "average" predicted probability of fracture for the entire study population that is close to the observed probability of fracture; however, this would not be a well-performing instrument. We also excluded studies that presented findings only in units of rate per person-years rather than as a probability over a fixed period of follow-up time. We required that included studies of the performance of risk assessment instruments were done in populations other than the instrument derivation cohort, as the focus of this review was determining how these instruments perform in patients other than those whose data was used to develop the risk assessment instrument. Thus, we did not include studies in which the instruments were developed and validated in the same patients, or in which data from the study population was used in the development of the risk assessment instrument. We also excluded studies with a split-cohort design, in which the instrument was developed in one group of participants within a cohort and tested in a separate group of participants within that cohort.
Studies were assessed for potential inclusion in two stages, title/abstract and full-text. Studies that passed the title/abstract review were retrieved for full-text review. Foreign language studies were translated using the Google Translate translation system. All studies were assessed for inclusion/exclusion at the title/abstract stage by one reviewer (DLE); for any studies for which inclusion versus exclusion was unclear or there were questions about eligibility, a second reviewer (SN) assessed the studies to determine their eligibility for inclusion. All studies that were retrieved for full-text review were reviewed by two reviewers for inclusion (DLE and SN), and any disagreements about eligibility for inclusion were resolved by repeated review and discussion.
Data extraction
Data extracted from studies that met inclusion criteria included study location; year of publication; sociodemographics of participants; participant exclusion criteria; study funding source; study design details; number of study participants and dropouts/deaths; percentage of study participants who had osteoporosis, osteopenia, or history of osteoporotic fracture; risk assessment instrument evaluated and its components; types of fractures assessed; fracture follow-up time period; method of fracture ascertainment; risk assessment instrument thresholds or categories used to identify individuals at different levels of fracture risk; predicted fracture probability associated with each threshold/category; observed fracture probability over study time period for each threshold/ category; and analysis details. Data were initially extracted by one author (DLE), and checked for accuracy by another author (SN). We contacted several authors for missing results datafor example, when a figure in an included article showed a graph of predicted and observed fracture probabilities, but exact numbers were not presented.
Data analysis
Due to wide heterogeneity in included study characteristics, including multiple different fracture risk assessment instruments and thresholds/categories evaluated, and diverse populations in which they were assessed, meta-analysis of study findings was not performed. Instead, we qualitatively described study findings, describing different study characteristics and findings regarding the performance of evaluated fracture risk assessment tools in various study populations; and examined potential sources of bias.
Results
Literature search and study selection
Our literature search identified 19,949 unique records for review. Of these studies, 14 met criteria for inclusion in this systematic review [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Figure 1 is a flow diagram that shows the number of records identified from databases and other sources; number of studies excluded at each stage of review and reasons for exclusion of full-text records reviewed (for example, 24 studies were excluded for not providing predicted and observed fracture probabilities for different risk thresholds/categories ); and number of studies that qualified for inclusion.
Characteristics of included studies Table 1 details characteristics of the included studies. All included studies were peer-reviewed English-language journal articles published between 2005 and 2011, and all were cohort studies. Two Canadian cohorts were used in multiple studies-the Manitoba BMD cohort (four studies) [10, 14, 18, 20] and Canadian Multicentre Osteoporosis Study (CaMOS) cohort (three studies) [10, 15, 17] ; several studies assessed risk instrument performance in more than one cohort population. There was considerable heterogeneity among the study characteristics. Six studies assessed the WHO's FRAX instrument [10-12, 14, 16, 22] ; two studies each evaluated the original Canadian Association of Radiologists and Osteoporosis Canada (CAROC) instrument [15, 18] , the Garvan Institute fracture risk calculator [11, 15] , or the 2001 Kanis risk algorithm (age and hip BMD T-score) [19, 20] ; and the remainder of studies each assessed different risk instruments. Several studies assessed multiple risk instruments. Most studies assessed a risk instrument that included a BMD component. Five studies were done in Canada, five in Europe (three in the UK, one in Denmark, and one in Poland), two in the USA, one in Japan, and one in New Zealand. Nine studies included female participants only; and four of the other six studies had predominantly female participants, including three studies using the Manitoba BMD cohort. The average age of study participants ranged from 47 to 74, and sample sizes ranged from 501 to over two million participants. The majority of studies did not report the race/ethnicity of their participants; however, all but one of the studies were conducted in countries with predominantly white populations.
Six studies reported the prevalence of osteoporosis by DXA criteria in their study population, with prevalences ranging from 11 to 30.9 %. Ten studies reported prior fracture history of participants, with prevalences ranging from 0.6 to 33.5 %; however, two studies that reported prior fracture prevalences of greater than 30 % did not specify whether they were fragility fractures [11, 22] . Five studies excluded participants who were receiving or had received medical therapy for osteoporosis or hormone replacement therapy (HRT) [11-13, 19, 22] , and two studies excluded individuals who had a history of osteoporotic fracture [16, 21] . The majority of studies did not report details about the medical comorbidities or medication use of their study participants; however, several studies reported that their participants were relatively healthy. Most studies reported 10-year fracture outcomes. The majority of studies reported combined probabilities of multiples types of osteoporotic fractures (ex. hip, vertebral, forearm); two studies reported hip fracture probabilities only [13, 16] . Approximately equal numbers of studies ascertained fracture occurrence by medical records review versus study participant self-report.
Performance of clinical risk assessment tools for predicting absolute future fracture risk (calibration) Table 2 shows individual study findings for predicted and observed probabilities of fracture for different risk thresholds/categories. A slight majority of studies reported good calibration of at least one risk assessment instrument evaluated [9-12, 14, 15, 20, 21] , with observed fracture probabilities being close to predicted probabilities at different risk thresholds/categories evaluated; however, two of these studies involved evaluation of the same risk assessment instrument (FRAX) in the same study cohort [10, 14] . Conversely, seven studies reported suboptimal calibration of at least one evaluated risk instrument [11, 13, [16] [17] [18] [19] 22] .
The six studies that assessed the calibration of the FRAX risk assessment instrument reported mixed performance. Two of these studies assessed different forms of FRAX in one Canadian cohort, the Manitoba BMD cohort, and these studies found good calibration of FRAX in that cohort [10, 14] . The other four studies that assessed FRAX were performed in different countries (the UK, New Zealand, Japan, and France) [11, 12, 16, 22] , and three of these studies reported suboptimal FRAX calibration [11, 16, 22] . Thus, suboptimal calibration of FRAX was found in three of the five separate cohorts in which this tool was evaluated. Three studies assessed the calibration of FRAX with a BMD component as well as without a BMD component, and found comparable performance of the FRAX model with and without a BMD component [11, 12, 22] . Two studies assessed the Garvan Institute fracture risk calculator-one study by Langsetmo and colleagues found the calibration to be generally good, except for overprediction of risk in the highest risk quintiles [15] ; another study by Bolland and colleagues found the instrument to be well calibrated for Garvan-defined osteoporotic fractures but overestimate hip fractures [11] . Two studies assessed the original CAROC system and found poor calibration [15, 18] . Two studies assessed the 2001 Kanis risk algorithm that includes age and BMD, with mixed calibration performance findings [19, 20] . One study assessed the QFracturesScores risk instrument, and found good instrument calibration in a large nationally representative cohort in the UK [21] . The remainder of risk assessment instruments in included studies were also assessed in only one study; the findings with respect to the calibration of these other risk assessment instruments assessed were mixed, with some instruments found to have good calibration in the study populations in which they were assessed (e.g., the updated CAROC system) [9, 10, 20] , and others found to have poor calibration in the population in which they were assessed [13, 17] .
A similar proportion of the relatively simple risk assessment instruments (≤5 clinical variables; including the Garvan Institute fracture risk calculator, 2001 Kanis risk algorithm, and 10-year fracture risk according to age only) evaluated in included studies were found to have good calibration when compared with studies that assessed complex risk assessment instruments (>5 clinical variables; including FRAX, QFractureScores, CAROC system, Fracture Risk Calculator (FRC), an Excel spreadsheet-based model of fracture risk [17] , and a risk score predicting the 5-year risk of fracture [9] ), with a slight majority of both simple and complex instruments found to have good calibration. There were also no clear differences noted in the proportion of risk assessment instruments with a BMD component versus those without a BMD component found to have good versus poor calibration. Additionally, no clear differences were apparent in the calibration performance of risk assessment instruments evaluated in female versus male study participants, although data for men were limited to only a few studies.
Two out of five studies that exclude participants who had received medical therapy for osteoporosis or hormone therapy reported good calibration of an evaluated risk assessment instrument for fracture prediction, whereas six of the nine studies that did not exclude participants who had received osteoporosis treatment or hormone replacement therapy reported good risk instrument calibration.
Study quality/potential sources of bias
We compared studies on several quality measures to identify potential sources of bias in study findings (Table 2 ). No clear relationship was apparent between study size (number of study participants) and reported instrument calibration performance. Most studies did not indicate the percentage of the eligible study cohort who were lost to follow-up or died during the fracture risk prediction period. Six included studies were supported by pharmaceutical industry funding or had an author who received support from a pharmaceutical company [9, 10, 14, 15, 17, 18] ; no clear relationship was apparent between a pharmaceutical industry relationship and the reported calibration performance of fracture risk assessment instruments. Eight studies had at least one author who was involved in the development of the risk assessment instrument evaluated [9, 10, 13-15, 17, 18, 22] ; no clear relationship was apparent between having an author who was involved in risk tool development and reported instrument calibration performance.
A similar proportion of studies that used methods of medical records review to identify fractures reported good risk assessment instrument calibration compared with studies that assessed fractures by participant self-report. Half of included studies were missing data on at least one instrument clinical risk factor, and used substituted data for the missing information [9, 10, [12] [13] [14] [15] [16] 21] ; a higher proportion of these studies reported good instrument calibration compared with studies that were not missing instrument risk factor data. Most studies used estimation methods (Kaplan-Meier estimates) to estimate observed fracture probabilities over the follow-up period of interest in the absence of follow-up over the entire fracture prediction period of interest for all study participants; however, four studies did not use estimation methods due to performing their analyses on subjects for whom data on fracture outcomes was available for the entire fracture risk prediction period of interest [12, 17, 19, 22] ; three of these studies reported suboptimal risk assessment instrument calibration.
Discussion
This systematic review of the performance of osteoporosis clinical fracture risk assessment instruments for predicting absolute future fracture risk in populations other than their development cohorts found that relatively few studies have been performed to date to externally validate the performance of fracture risk assessment instruments, and these studies are heterogeneous in terms of assessing a variety of risk assessment instruments in different patient populations. Of the studies that have been done, findings are mixed with respect to how well instruments perform in terms of observed fracture probabilities matching predicted fracture probabilities, i.e., calibration. Additionally, many of the studies that have assessed the calibration of fracture risk assessment instruments have methodological features making them susceptible to bias, which makes interpretation of their findings more difficult. A recent paper by Kanis et al. highlighted several methodological flaws in some external validation studies of FRAX [47] , for example not incorporating the death hazard when assessing the tool's performance. FRAX was the only risk assessment instrument for which we found more than two studies assessing calibration in populations unrelated to the development cohorts-and the studies that evaluated this instrument found mixed performance results. Two of the studies assessing FRAX instrument calibration were performed in one country, Canada; however, both of these studies assessed FRAX's performance in one clinical referral population cohort, the Manitoba BMD cohort-which makes it difficult to draw conclusions about the generalizability of these findings for the general Canadian population [10, 14] . One large study that evaluated the performance of QFractureScores in a nationally representative cohort in the UK found good calibration of this risk assessment instrument [21] , providing compelling evidence that this instrument is well calibrated for the general population of the UK. Findings on the performance of other evaluated risk instruments were limited and mixed.
We are not aware of any prior comprehensive systematic review that has assessed the performance of osteoporosis absolute fracture risk assessment instruments by comparing predicted fracture probabilities to observed fracture probabilities (i.e., calibration) in populations other than the risk instrument development cohorts. A more general review on prognostic instruments to identify patients at risk for osteoporotic fractures by Steurer et al. in 2011 [48] highlighted that there have been few validation studies of prognostic instruments to identify patients at risk for osteoporotic fractures, and significant heterogeneity in study characteristics, prediction variables, outcome assessment, and follow-up time periods; however, the review by Steurer et al. excluded the FRAX instrument. Additionally, another recent systematic review of the literature on fracture risk assessment instruments assessed another measure of their performance, specifically their ability to discriminate individuals who fracture from those who do not (i.e., discrimination), using area under the receiver-operating characteristic curve (AUC) as the performance outcome measure of interest [49] . The prior systematic review done by Nelson et al. in 2010 was part of an evidence update relevant to screening for osteoporosis for the U.S. Preventive Services Task Force, and identified eleven studies that reported AUCs for fracture prediction for 11 different risk instruments; AUCs varied from 0.48 to 0.89 [49] . The authors concluded that risk assessment instruments are modest predictors of fracture. Additionally, Nelson et al. found that simple models containing only a few clinical variables performed as well as more complex instruments for fracture prediction [49] . Our study, which compared predicted vs. observed fracture probabilities for risk assessment instruments, provides a different measure of the performance of these instruments-how well calibrated they are. AUCs, although they provide a useful comparison for overall instrument performance in terms of discriminating individuals who fracture from those who do not (i.e., discrimination), do not provide information on risk assessment instrument performance in terms of calibration at specific risk thresholds/categories-which is essential information for a clinician to know when using an instrument [50] . Thus, our findings complement those of the review by Nelson et al. in summarizing the evidence on a different and important measure of the performance of fracture risk assessment instruments. Similar to Nelson et al., our findings indicate mixed performance results for different risk assessment instruments evaluated in various study populations; albeit for a difference measure of instrument performance (calibration rather than discrimination).
Several recent studies that have used AUCs as a performance measure have suggested that simple risk assessment instruments perform as well as more complex instruments for predicting future fracture risk [12, 49, 51] . Our study found that a slight majority of the relatively simple risk assessment instruments (which we defined as five or less clinical variables) evaluated were found to have good calibration, similar to the proportion of complex risk assessment instruments evaluated that were found to have good calibration. We also found no clear differences in the proportion of risk assessment instruments with a BMD component versus those without a BMD component that were found to have good versus poor calibration. Thus, our findings with respect to calibration provide further evidence that simple risk assessment instruments may perform as well as complex instruments; or at least that the literature does not provide compelling evidence that complex risk assessment instruments are necessarily better calibrated than simple instruments. However, it is important to note that although simple risk assessment instruments may perform similarly to complex instruments for a population in which the prevalence of secondary causes of osteoporosis (e.g., prolonged glucocorticoid use) is low, for individuals with secondary causes of osteoporosis these tools will likely not perform as well; such individuals would likely benefit from use of a complex risk assessment instrument.
Our systematic review highlights that conclusive evidence is lacking with respect to the external validity of available fracture risk assessment instruments for predicting future fracture risk in different patient populations in which they may be used. Few studies have been done to assess the external validity of fracture risk assessment instruments, and there are a number of potential sources of bias in most studies that have been done. Despite the dearth of studies demonstrating calibration and external validity of these instruments, they are growing in clinical use and several guidelines groups have recommended their use [8] . More high-quality studies are needed to assess the performance of osteoporosis fracture risk assessment instruments in terms of their calibration in cohorts independent of their development cohorts, in populations representative of those in which they may be used, so that physicians and patients can be confident in their use to make clinical care decisions. Further studies would also help to identify best performing instruments in different patient populations. Additionally, more studies need to be done to assess the performance of risk assessment instruments in men, for whom there is a particular dearth of evidence.
Our study has several limitations. Although we performed an exhaustive literature search, we may have missed some relevant citations, particularly those that were published after our literature search was performed. Additionally, we were unable to perform a meta-analysis of the included studies due to considerable study heterogeneity in key characteristics. Furthermore, the studies included in our systematic review assessed the performance of risk assessment instruments in cohorts from which data on fracture outcomes was primarily collected in the 1990s and the early 2000s, and may not reflect the exact performance of these risk assessment instruments today-as osteoporotic fracture rates are changing over time [52] [53] [54] , the performance of risk assessment instruments would be expected to change, and the calibration of the instruments would need to be reassessed. In addition, we included studies that included patients on osteoporosis therapy that can reduce fracture risk, which may alter the observed risk. Our study also had several notable strengths. We performed an exhaustive literature search for studies that evaluated the performance of fracture risk assessment instruments by comparing predicted fracture probability to observed fracture probability. We are not aware of any other comprehensive systematic review of the calibration of fracture risk assessment instruments.
In conclusion, our systematic review found that relatively few studies have been done that assess the calibration of fracture risk assessment instruments in populations separate from their development cohorts; of the studies that have been done on this topic, findings are mixed with respect to risk assessment instrument performance, and many studies have methodological limitations that make susceptibility to bias a concern. Further high-quality studies to assess the calibration of risk assessment instruments in populations in which they may be used are needed before the widespread use of individual risk assessment instruments can be recommended.
